kabutan

Heartseed Inc.(219A) Summary

219A
TSE Growth
Heartseed Inc.
1,931
JPY
-41
(-2.08%)
Jan 29, 3:30 pm JST
12.62
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
1,923
Jan 29, 9:34 pm JST
Summary Chart Historical News Financial Result
PER
224.8
PBR
6.14
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
1,972 JPY 12.87 USD
Previous Close Jan 28
1,972 JPY 12.92 USD
High Jan 29, 9:00 am
1,978 JPY 12.92 USD
Low Jan 29, 9:13 am
1,922 JPY 12.55 USD
Volume
210,900
Trading Value
0.41B JPY 2.68M USD
VWAP
1941.52 JPY 12.69 USD
Minimum Trading Value
193,100 JPY 1,262 USD
Market Cap
0.04T JPY 0.29B USD
Number of Trades
970
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
4,003
1-Year High Oct 2, 2025
50,688
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 884,700 1,806,200 2.04
Jan 16, 2026 935,400 1,823,400 1.95
Jan 9, 2026 937,200 1,858,400 1.98
Dec 26, 2025 941,400 1,867,800 1.98
Dec 19, 2025 959,100 1,853,000 1.93
Company Profile
Heartseed Inc. engages in the research and development of regenerative medicine products using iPS cells for cardiac regeneration.
Sector
Pharmaceuticals
Heartseed Inc. is a regenerative medicine venture originating from Keio University. The company is advancing the development of "cardiac regenerative medicine," a treatment method that involves transplanting micro-tissues (cardiac spheroids) derived from iPS cell-based cardiomyocytes into the heart, aiming to establish safety and efficacy. Heartseed possesses proprietary technologies, including techniques for producing high-purity cardiomyocytes and transplantation devices. With a vision for global expansion of cardiac regenerative medicine using allogeneic iPS cell-derived cardiac spheroids, the company entered into an exclusive worldwide technology partnership and licensing agreement with Novo Nordisk, a global pharmaceutical giant headquartered in Denmark, in May 2021.